Neoadjuvant cisplatin plus vinblastine chemotherapy in locally advanced non-small cell lung cancer

D. H. Johnson, J. Strupp, F. A. Greco, J. Stewart, W. Merrill, A. Malcolm, K. R. Hande, J. D. Hainsworth

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Twenty-eight patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) received neoadjuvant chemotherapy with cisplatin (120 mg/m2 on days 1 and 29) and vinblastine (4 mg/m2 weekly for 6 weeks). At the completion of induction chemotherapy, all patients were assessed for resectability. Those patients judged to be resectable underwent thoracotomy. All remaining patients received thoracic radiation therapy (5500 cGy) followed by additional chemotherapy in those patients responding to neoadjuvant treatment. There were 15 partial responses to neoadjuvant chemotherapy for an overall response rate of 54% (95% confidence interval, 36% to 71%). Only five partially responding patients (18%) were thought to have had sufficient tumor regression to allow for a potentially curative resection. However, a complete resection was done in only two patients. Overall median survival was 12 months (range, 4 to 72 months) with 1-year, 2-year, and 3-year survival rates of 54%, 39%, and 11%, respectively. The primary toxicity associated with neoadjuvant chemotherapy was moderate to severe (Eastern Cooperative Oncology Group Grade 3 or 4) nausea and emesis in 25% of patients. Hematologic toxicity was relatively modest; only one patient had Grade 4 leukopenia (< 1000/μl). Fever and neutropenia were uncommon, and there were no documented septic episodes or treatment-related deaths. Compared with historic controls treated with radiation therapy alone, cisplatin-based neoadjuvant chemotherapy appeared to improve the median and long-term survival of Stage III NSCLC patients modestly.

Original languageEnglish (US)
Pages (from-to)1216-1220
Number of pages5
JournalCancer
Volume68
Issue number6
StatePublished - 1991

Fingerprint

Vinblastine
Non-Small Cell Lung Carcinoma
Cisplatin
Drug Therapy
Radiotherapy
Induction Chemotherapy
Neoadjuvant Therapy
Survival
Leukopenia
Thoracotomy
Neutropenia
Nausea
Vomiting
Fever
Thorax
Survival Rate
Confidence Intervals

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Johnson, D. H., Strupp, J., Greco, F. A., Stewart, J., Merrill, W., Malcolm, A., ... Hainsworth, J. D. (1991). Neoadjuvant cisplatin plus vinblastine chemotherapy in locally advanced non-small cell lung cancer. Cancer, 68(6), 1216-1220.

Neoadjuvant cisplatin plus vinblastine chemotherapy in locally advanced non-small cell lung cancer. / Johnson, D. H.; Strupp, J.; Greco, F. A.; Stewart, J.; Merrill, W.; Malcolm, A.; Hande, K. R.; Hainsworth, J. D.

In: Cancer, Vol. 68, No. 6, 1991, p. 1216-1220.

Research output: Contribution to journalArticle

Johnson, DH, Strupp, J, Greco, FA, Stewart, J, Merrill, W, Malcolm, A, Hande, KR & Hainsworth, JD 1991, 'Neoadjuvant cisplatin plus vinblastine chemotherapy in locally advanced non-small cell lung cancer', Cancer, vol. 68, no. 6, pp. 1216-1220.
Johnson DH, Strupp J, Greco FA, Stewart J, Merrill W, Malcolm A et al. Neoadjuvant cisplatin plus vinblastine chemotherapy in locally advanced non-small cell lung cancer. Cancer. 1991;68(6):1216-1220.
Johnson, D. H. ; Strupp, J. ; Greco, F. A. ; Stewart, J. ; Merrill, W. ; Malcolm, A. ; Hande, K. R. ; Hainsworth, J. D. / Neoadjuvant cisplatin plus vinblastine chemotherapy in locally advanced non-small cell lung cancer. In: Cancer. 1991 ; Vol. 68, No. 6. pp. 1216-1220.
@article{8d274fe5702c41baa7c112ba6820acc7,
title = "Neoadjuvant cisplatin plus vinblastine chemotherapy in locally advanced non-small cell lung cancer",
abstract = "Twenty-eight patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) received neoadjuvant chemotherapy with cisplatin (120 mg/m2 on days 1 and 29) and vinblastine (4 mg/m2 weekly for 6 weeks). At the completion of induction chemotherapy, all patients were assessed for resectability. Those patients judged to be resectable underwent thoracotomy. All remaining patients received thoracic radiation therapy (5500 cGy) followed by additional chemotherapy in those patients responding to neoadjuvant treatment. There were 15 partial responses to neoadjuvant chemotherapy for an overall response rate of 54{\%} (95{\%} confidence interval, 36{\%} to 71{\%}). Only five partially responding patients (18{\%}) were thought to have had sufficient tumor regression to allow for a potentially curative resection. However, a complete resection was done in only two patients. Overall median survival was 12 months (range, 4 to 72 months) with 1-year, 2-year, and 3-year survival rates of 54{\%}, 39{\%}, and 11{\%}, respectively. The primary toxicity associated with neoadjuvant chemotherapy was moderate to severe (Eastern Cooperative Oncology Group Grade 3 or 4) nausea and emesis in 25{\%} of patients. Hematologic toxicity was relatively modest; only one patient had Grade 4 leukopenia (< 1000/μl). Fever and neutropenia were uncommon, and there were no documented septic episodes or treatment-related deaths. Compared with historic controls treated with radiation therapy alone, cisplatin-based neoadjuvant chemotherapy appeared to improve the median and long-term survival of Stage III NSCLC patients modestly.",
author = "Johnson, {D. H.} and J. Strupp and Greco, {F. A.} and J. Stewart and W. Merrill and A. Malcolm and Hande, {K. R.} and Hainsworth, {J. D.}",
year = "1991",
language = "English (US)",
volume = "68",
pages = "1216--1220",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Neoadjuvant cisplatin plus vinblastine chemotherapy in locally advanced non-small cell lung cancer

AU - Johnson, D. H.

AU - Strupp, J.

AU - Greco, F. A.

AU - Stewart, J.

AU - Merrill, W.

AU - Malcolm, A.

AU - Hande, K. R.

AU - Hainsworth, J. D.

PY - 1991

Y1 - 1991

N2 - Twenty-eight patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) received neoadjuvant chemotherapy with cisplatin (120 mg/m2 on days 1 and 29) and vinblastine (4 mg/m2 weekly for 6 weeks). At the completion of induction chemotherapy, all patients were assessed for resectability. Those patients judged to be resectable underwent thoracotomy. All remaining patients received thoracic radiation therapy (5500 cGy) followed by additional chemotherapy in those patients responding to neoadjuvant treatment. There were 15 partial responses to neoadjuvant chemotherapy for an overall response rate of 54% (95% confidence interval, 36% to 71%). Only five partially responding patients (18%) were thought to have had sufficient tumor regression to allow for a potentially curative resection. However, a complete resection was done in only two patients. Overall median survival was 12 months (range, 4 to 72 months) with 1-year, 2-year, and 3-year survival rates of 54%, 39%, and 11%, respectively. The primary toxicity associated with neoadjuvant chemotherapy was moderate to severe (Eastern Cooperative Oncology Group Grade 3 or 4) nausea and emesis in 25% of patients. Hematologic toxicity was relatively modest; only one patient had Grade 4 leukopenia (< 1000/μl). Fever and neutropenia were uncommon, and there were no documented septic episodes or treatment-related deaths. Compared with historic controls treated with radiation therapy alone, cisplatin-based neoadjuvant chemotherapy appeared to improve the median and long-term survival of Stage III NSCLC patients modestly.

AB - Twenty-eight patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) received neoadjuvant chemotherapy with cisplatin (120 mg/m2 on days 1 and 29) and vinblastine (4 mg/m2 weekly for 6 weeks). At the completion of induction chemotherapy, all patients were assessed for resectability. Those patients judged to be resectable underwent thoracotomy. All remaining patients received thoracic radiation therapy (5500 cGy) followed by additional chemotherapy in those patients responding to neoadjuvant treatment. There were 15 partial responses to neoadjuvant chemotherapy for an overall response rate of 54% (95% confidence interval, 36% to 71%). Only five partially responding patients (18%) were thought to have had sufficient tumor regression to allow for a potentially curative resection. However, a complete resection was done in only two patients. Overall median survival was 12 months (range, 4 to 72 months) with 1-year, 2-year, and 3-year survival rates of 54%, 39%, and 11%, respectively. The primary toxicity associated with neoadjuvant chemotherapy was moderate to severe (Eastern Cooperative Oncology Group Grade 3 or 4) nausea and emesis in 25% of patients. Hematologic toxicity was relatively modest; only one patient had Grade 4 leukopenia (< 1000/μl). Fever and neutropenia were uncommon, and there were no documented septic episodes or treatment-related deaths. Compared with historic controls treated with radiation therapy alone, cisplatin-based neoadjuvant chemotherapy appeared to improve the median and long-term survival of Stage III NSCLC patients modestly.

UR - http://www.scopus.com/inward/record.url?scp=0025989806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025989806&partnerID=8YFLogxK

M3 - Article

C2 - 1651802

AN - SCOPUS:0025989806

VL - 68

SP - 1216

EP - 1220

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -